News | July 21, 2025
Aarti Drugs posts Q1 FY26 PAT higher at Rs. 54 Cr
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
Aims to support healthcare practitioners with evidence-based cough categorization tools that enable choosing the right molecules for effective & targeted relief from cough
This marks the fourth acquisition by Corona Remedies from multinational corporations
The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
India’s nutraceutical industry is expected to reach over US$ 22 billion in 2025
The program will offer a structured and immersive learning experience for over 20,000 healthcare professionals across more than 10 cities
The agreement includes plans for distribution, technology transfer, local manufacturing, new pharmaceutical product development
The global TCIM market is expected to reach nearly US$ 600 billion by 2025
Subscribe To Our Newsletter & Stay Updated
